Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease

Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease

Due to the population aging and the accumulation of concomitant diseases, the prevalence of atrial fibrillation (AF) as the most common arrhythmia is increasing. On the other hand, 14% of the population has chronic kidney disease (CKD). These conditions are often combined with each other causing a p...

Full description

Bibliographic Details
Main Authors:	N. Sh. Zagidullin, P. A. Davtyan
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2021-10-01
Series:	Российский кардиологический журнал
Subjects:	atrial fibrillation chronic kidney disease direct oral anticoagulants warfarin bleeding thromboembolism
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4676

Similar Items

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: V. I. Petrov, et al.
Published: (2019-09-01)

Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran
by: N. A. Novikova, et al.
Published: (2021-05-01)

Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2020-05-01)

A call to action for anticoagulation stewardship
by: Allison E. Burnett, et al.
Published: (2022-07-01)

Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients
by: Masahiko Umei, MD, et al.
Published: (2017-10-01)

Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation
by: Nemin Chen, et al.
Published: (2018-11-01)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: Antonio de Padua Mansur, et al.
Published: (2012-01-01)

Usage and safety of direct oral anticoagulants at patients with atrial fibrillation and planned diagnostic procedures, interventions, and surgery
by: Marko Mornar Jelavic, et al.
Published: (2019-01-01)

Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2019-03-01)

ANTICOAGULATION CONTROL AMONG PATIENTS WITH ATRIAL FIBRILLATION
by: Amer Rauf, et al.
Published: (2020-12-01)

Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF)
by: Yuji Murakawa, MD, et al.
Published: (2017-06-01)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
by: Seo Yeon Yoo, et al.
Published: (2022-05-01)

Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance
by: Riccardo Vio, et al.
Published: (2021-03-01)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
by: Mette Søgaard, et al.
Published: (2019-06-01)

Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
by: Michele Magnocavallo, et al.
Published: (2020-12-01)

Oral Anticoagulant Treatment and the Risk of Dementia in Patients With Atrial Fibrillation: A Population‐Based Cohort Study
by: Woldesellassie M. Bezabhe, et al.
Published: (2022-04-01)

Anticoagulation for Atrial Fibrillation in End-stage Kidney Disease
by: Gavin Lee, et al.
Published: (2015-10-01)

Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation Therapy
by: Reinhold Kreutz, et al.
Published: (2024-01-01)

Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease
by: I. S. Daabul, et al.
Published: (2016-11-01)

How to level the risk of bleeding while taking anticoagulant therapy in patients with atrial fibrillation?
by: Svetlana A. Berns, et al.
Published: (2022-01-01)

Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)
by: A. I. Mironova (Staroverova), et al.
Published: (2020-10-01)

Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
by: Anetta Undas, et al.
Published: (2019-12-01)

Changes in Prescribing Antithrombotic Therapy in Patients with Atrial Fibrillation in the Multidisciplinary Hospital in Volgograd from 2012 to 2020
by: A. S. Gerasimenko, et al.
Published: (2022-01-01)

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage
by: A. S. Gerasimenko, et al.
Published: (2021-05-01)

Efficacy and safety of anticoagulation in thyrotoxic atrial fibrillation: a systematic review and meta-analysis
by: Eng-Loon Tng, et al.
Published: (2022-05-01)

Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by New Oral Anticoagulants, to be cautiously used
by: Francesco Orso, et al.
Published: (2013-12-01)

Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
by: Tae-Min Rhee, et al.
Published: (2022-06-01)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
by: Sirote Luengsupabul, et al.
Published: (2020-06-01)

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
by: Alexandros Briasoulis, et al.
Published: (2020-02-01)

Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey
by: Emre Ozdemir, et al.
Published: (2020-01-01)

Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry
by: Yasuo Okumura, et al.
Published: (2017-08-01)

Clinical outcomes and anticoagulation therapy in elderly non‐valvular atrial fibrillation and heart failure patients
by: Shota Ikeda, et al.
Published: (2024-04-01)

SAFETY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: A TWO-YEAR COHORT STUDY
by: A. V. Zhilenko, et al.
Published: (2017-07-01)

MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015-09-01)

Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data
by: Youn Kyung Kee, et al.
Published: (2023-09-01)

New Insights into Anticoagulation in Atrial Fibrillation
by: Xiaohan Fan, MD, et al.
Published: (2011-01-01)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
by: Krishna N. Pundi, et al.
Published: (2021-12-01)

Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis
by: Xinxing Gao, et al.
Published: (2022-05-01)

Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation
by: Yuichiro Sagawa, et al.
Published: (2018-08-01)

Anticoagulant Treatment in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: Marta Popović, et al.
Published: (2021-01-01)